Patents Assigned to The Salk Institute for Biological Studies
  • ULK1 COMPOSITIONS, INHIBITORS, SCREENING AND METHODS OF USE
    Publication number: 20160289651
    Abstract: This disclosure relates to methods and compositions useful for the treatment of cancer and diseases and disorders associated with autophagy.
    Type: Application
    Filed: February 24, 2016
    Publication date: October 6, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Reuben J. Shaw, Daniel F. Egan, Maria Mihaylova, David Shackelford
  • Methods for treating metabolic disorders using FGF
    Patent number: 9446097
    Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: September 20, 2016
    Assignee: Salk Institute for Biological Studies
    Inventors: Johan W. Jonker, Michael Downes, Ronald M. Evans, Jae Myoung Suh
  • Epigenomic induced pluripotent stem cell signatures
    Patent number: 9428811
    Abstract: Provided herein are methods of characterizing the epigenetic signature of human induced pluripotent stem cells. The methods are useful in identifying human induced pluripotent stem cells (hiPSCs), diagnostic markers for incomplete hiPSCs reprogramming, and characterization of the efficacy of different reprogramming techniques.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: August 30, 2016
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Joseph R. Ecker, Ryan Lister
  • CHIMERIC FIBROBLAST GROWTH FACTOR (FGF) 2/FGF1 PEPTIDES AND METHODS OF USE
    Publication number: 20160237133
    Abstract: The present disclosure provides chimeric proteins having an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion of fibroblast growth factor (FGF) 2 and the C-terminus comprises a portion of an FGF1 protein. Such FGF2/FGF1 chimeras can further include a fibroblast growth factor receptor (FGFR) 1c-binding protein, a ?-Klotho-binding protein, or both. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Application
    Filed: April 6, 2016
    Publication date: August 18, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins
  • Sonogenic Stimulation of Cells
    Publication number: 20160220672
    Abstract: The invention provides compositions featuring TRP-4 polypeptides and polynucleotides, methods for expressing such polypeptides and polynucleotides in a cell type of interest, and methods for inducing the activation of the TRP-4 polypeptide in neurons and other cell types using ultrasound.
    Type: Application
    Filed: September 2, 2015
    Publication date: August 4, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Sreekanth H. Chalasani, Stuart Ibsen
  • NEUROPROTECTIVE POLYPHENOL ANALOGS
    Publication number: 20160206609
    Abstract: The present invention provides neuroprotective polyphenol compounds, which can be synthetic analogs of fisetin, baicalein or chlorogenic acid, that maintain neuroprotective, anti-inflammatory, glutathione promoting, and/or antioxidant properties. The neuroprotective polyphenol compounds are useful for promoting, enhancing and/or increasing neuron protection, growth and/or regeneration. The polyphenol compounds further find use for increasing and or maintaining intracellular glutathione (GSH) levels. The polyphenol compounds are also useful for treating, preventing, mitigating and/or delaying neurodegenerative conditions, including diabetes, Parkinson's disease, Huntington's disease, Alzheimer's disease, non-Alzheimer's dementias, multiple sclerosis, traumatic brain injury, spinal cord injury or ALS.
    Type: Application
    Filed: February 26, 2016
    Publication date: July 21, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: David R. Schubert, Pamela A. Maher, Chandramouli Chiruta
  • CHIMERIC FIBROBLAST GROWTH FACTOR (FGF) 2/FGF1 PEPTIDES AND METHODS OF USE
    Publication number: 20160206695
    Abstract: The present disclosure provides chimeric proteins having an N-terminus coupled to a C-terminus, wherein the N-terminus comprises an N-terminal portion of fibroblast growth factor (FGF) 2 and the C-terminus comprises a portion of an FGF1 protein, wherein the chimeric protein comprises at least 95% sequence identity to SEQ ID NO: 9, 10, 11, 12 or 13. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.
    Type: Application
    Filed: April 6, 2016
    Publication date: July 21, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Jae Myoung Suh, Michael Downes, Ronald M. Evans, Annette Atkins, Senyon Choe, Witek Kwiatkowski
  • Induced pluripotent stem cell produced by transfecting a human neural stem cell with an episomal vector encoding the Oct4 and Nanog proteins
    Patent number: 9340775
    Abstract: Methods and compositions for the generation and use of footprint-free human induced pluripotent stem cells are provided.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: May 17, 2016
    Assignee: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Alysson R. Muotri, Fred H. Gage, Maria C. N. Marchetto
  • MEDIA COMPOSITIONS FOR NEURONAL CELL CULTURE
    Publication number: 20160108361
    Abstract: Provided herein are, inter alia, are media compositions useful for culturing neural cells. In particular, the compositions provided herein mimic important physiological conditions in the living brain and sustain neural activity. The media compositions provided herein improve the efficiency of human neuron maturation and promote synaptic function in long-term in vitro cultures.
    Type: Application
    Filed: April 17, 2014
    Publication date: April 21, 2016
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Fred H. Gage, Cedric Bardy
  • VITAMIN D RECEPTOR/SMAD GENOMIC CIRCUIT GATES FIBROTIC RESPONSE
    Publication number: 20160106762
    Abstract: The present disclosure provides compositions that include a nanoparticle and a compound that increases the biological activity of the vitamin D receptor (VDR) (e.g., a VDR agonist), and methods of using such compounds to increase retention or storage of vitamin A, vitamin D, and/or lipids by a cell, such as an epithelial or stellate cell. Such methods can be used to treat or prevent fibrosis.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 21, 2016
    Applicants: Salk Institute for Biological Studies, The University of Sydney
    Inventors: Ning Ding, Michael Downes, Christopher Liddle, Ronald M. Evans
  • METHODS OF TREATING MUSCULAR DYSTROPHY
    Publication number: 20160101086
    Abstract: Disclosed herein are methods of improving muscular health, such as enhancing muscle regeneration, maintenance, or repair. In some examples, the method includes administering to the subject an effective amount of an agent capable of increasing activity or expression of estrogen receptor-related gamma (ERR?), related receptors ERR? or ?, or ERR-regulated metabolic and angiogenic genes, thereby enhancing muscle regeneration, maintenance, or repair. In some examples, the methods are utilized to treat a subject with one or more signs or symptoms of muscular dystrophy, such as, but not limited to Duchenne muscular dystrophy. In some examples, the disclosed methods further include selecting a subject in need of enhancing muscle regeneration, maintenance, or repair.
    Type: Application
    Filed: December 17, 2015
    Publication date: April 14, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Michael Downes, Ruth T. Yu, Vihang A. Narkar, Ronald M. Evans
  • VITAMIN D RECEPTOR AGONISTS TO TREAT DISEASES INVOLVING CXCL12 ACTIVITY
    Publication number: 20160089385
    Abstract: Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 31, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Mara Sherman, Michael Downes, Ronald M. Evans
  • METHODS FOR HEART REGENERATION
    Publication number: 20160068863
    Abstract: Methods for heart regeneration are provided. The invention provided herein includes methods of modulating proliferation of cardiomyocytes using small molecules and micro RNAs. In embodiments, the methods provided may be used to increase proliferation or cardiomyocytes. Further provided are methods to be used for the treatment of myocardial infarction.
    Type: Application
    Filed: November 19, 2015
    Publication date: March 10, 2016
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Aitor Aguirre, Ignacio Sancho-Martinez, Juan Carlos Izpisua-Belmonte
  • ADENOVIRAL ASSEMBLY METHOD
    Publication number: 20160053235
    Abstract: Methods of assembling modified adenoviruses, libraries of adenoviral gene modules and compositions thereof are provided herein.
    Type: Application
    Filed: November 9, 2015
    Publication date: February 25, 2016
    Applicant: Salk Institute for Biological Studies
    Inventors: Clodagh O'Shea, Colin Powers
  • Medical food for cognitive decline
    Patent number: 9254280
    Abstract: Nutraceutical formulations that improve cognitive function in adults diagnosed with neurodegenerative disease are provided, which comprise a combination of fisetin and DHA.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: February 9, 2016
    Assignees: The Regents of the University of California, Salk Institute for Biological Studies, U.S. Department of Veterans Affairs
    Inventors: Gregory M. Cole, Sally A. Frautschy, David R. Schubert, Pamela A. Maher
  • USE OF POLYCLONAL AND MONOCLONAL ANTIBODIES SPECIFIC FOR 3-PHOSPHOHISTIDINE
    Publication number: 20160033516
    Abstract: Isolated monoclonal antibodies and antigen binding fragments are disclosed herein that specifically bind polypeptides comprising a histidine phosphorylated at N3 (3-pHis). Nucleic acids encoding these antibodies, vectors including these nucleic acids, and host cells transformed with these vectors and nucleic acids are also disclosed. Methods are also disclosed for using these antibodies, such as for detection of polypeptides comprising a histidine phosphorylated at N3 (3-pHis), detection of a tumor, monitoring the effectiveness of therapeutic agent, and identifying antibiotics. In some embodiments, the methods can be used to investigate signal transduction pathways.
    Type: Application
    Filed: July 1, 2015
    Publication date: February 4, 2016
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Tony Hunter, Stephen Rush Fuhs, Jill Meisenhelder
  • PPAR AGONISTS
    Publication number: 20160023991
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Application
    Filed: October 2, 2015
    Publication date: January 28, 2016
    Applicants: Salk Institute for Biological Studies, Mitobridge, Inc.
    Inventors: Ronald M. Evans, Michael Downes, Thomas J. Baiga, Joseph P. Noel, Emi Kanakubo Embler, Weiwei Fan, John F.W. Keana, Mark G. Bock, Arthur F. Kluge, Mike A. Patane
  • Compositions and methods for inhibiting human host factors required for influenza virus replication
    Patent number: 9238815
    Abstract: This application relates to the modulation of host cell factors required for influenza virus replication. The application relates to compounds, including nucleic acid compounds (such as, e.g., small interfering RNAs (siRNAs)) and small molecules, that target human host cell factors involved in influenza virus replication, and the use of such compounds for modulating influenza virus replication and as antiviral agents. The application also relates to methods of treating an influenza virus infection and methods of treating or preventing a symptom or disease associated with influenza virus infection, comprising administering to a subject a composition comprising a compound, such as a nucleic acid compound (e.g., an siRNA) or small molecule, that targets a human host cell factor involved in influenza virus replication.
    Type: Grant
    Filed: December 10, 2010
    Date of Patent: January 19, 2016
    Assignees: Icahn School of Medicine at Mounta Sinai, Salk Institute for Biological Studies, Sanford-Burnham Medical Research Institute
    Inventors: Megan Shaw, Peter Palese, Adolfo Garcia-Sastre, Silke Stertz, John Young, Renate König, Sumit Chanda
  • ONCOLYTIC ADENOVIRUS COMPOSITIONS
    Publication number: 20150374766
    Abstract: An adenovirus comprising an E1A polypeptide comprising one or more modifications and comprising an E4orf6/7 polypeptide comprising one or more modifications is described. Compositions and kits comprising the modified adenoviruses are also described. Further described is a method of treating a proliferative disorder in a subject comprising administering to the subject an adenovirus comprising the E1A polypeptide comprising one or more modifications and comprising the E4orf6/7 polypeptide comprising one or more modifications.
    Type: Application
    Filed: September 14, 2015
    Publication date: December 31, 2015
    Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIES
    Inventors: Clodagh O'Shea, Shigeki Miyake-Stoner
  • Methods for heart regeneration
    Patent number: 9220721
    Abstract: Methods for heart regeneration are provided. The invention provided herein includes methods of modulating proliferation of cardiomyocytes using small molecules and micro RNAs. In embodiments, the methods provided may be used to increase proliferation or cardiomyocytes. Further provided are methods to be used for the treatment of myocardial infarction.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: December 29, 2015
    Assignee: Salk Institute for Biological Studies
    Inventors: Aitor Aguirre, Ignacio Sancho-Martinez, Juan Carlos Izpisua-Belmonte